BioCentury | Jun 26, 2020
Distillery Therapeutics

Blocking cGAS for colitis

DISEASE CATEGORY: Gastrointestinal INDICATION: Colitis Colitis may be treatable by targeting cGAS, a cytosolic DNA sensor that triggers inflammatory signaling through STING activity. In a mouse model of chemically induced colitis, systemic GSDMD knockout exacerbated...
BioCentury | May 6, 2020
Emerging Company Profile

Ventus: A structural edge in innate immunity targets

Ventus emerged from stealth on Wednesday with a Versant-led $60 million series A round and a drug discovery platform designed to tackle one of the biggest challenges of targeting innate immune signaling: the lack of...
BioCentury | Jan 28, 2020
Company News

Quenching the flames of inflammatory cell death

Emerging from stealth Monday with a $50 million A round, Quench Bio is targeting the nexus of inflammatory cell death. RA Capital led the round with participation from new investor AbbVie Ventures. Atlas Venture and...
BioCentury | Oct 8, 2019

Inhibiting caspase-mediated pyroptosis for graft-versus-host disease

DISEASE CATEGORY: Transplant INDICATION: Graft-versus-host disease (GvHD) Inhibiting CASP4 or CASP5, the human homologs of murine pyroptosis activator CASP11, or the downstream mediators GSDMD and IL-1α could prevent GvHD in leukemia patients undergoing allogeneic hematopoietic...
BioCentury | Aug 29, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Sepsis Cell culture and mouse studies identified a GSDMD inhibitor that could help treat sepsis. In vitro , the previously identified necroptosis inhibitor necrosulfamide bound GSDMD with a K d of 32 μM. In mouse...
BioCentury | Aug 28, 2018
Preclinical News

Stealth start-up Quench among teams tying protein to inflammatory cell death

Atlas Venture-backed start-up Quench Bio has partnered with a Max Planck Institute for Infection Biology team to target an inflammatory cell death pathway implicated in inflammatory and autoimmune diseases. The company, which is funded by...
BioCentury | Jan 4, 2018
Distillery Therapeutics

Ophthalmic disease

INDICATION: Age-related macular degeneration (AMD) Patient sample, cell culture and mouse studies suggest inhibiting cGAS, CASP4, GSDMD, IFNB1, IFNAR1, IRF3 or STAT2 could help treat geographic atrophy. In tissue samples from patients, levels of cGAS,...
BioCentury | Oct 27, 2017
Preclinical News

Cell study points to new antibiotic strategy

A study in Cell shows granzyme B (GrB; GZMB), an immune cell protease, kills diverse bacterial species by shutting down multiple conserved survival pathways. The authors suggest compounds that mimic the protease’s mechanism could treat...
Items per page:
1 - 8 of 8